NYSE:ABBV - AbbVie Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$106.91 +0.68 (+0.64 %)
(As of 05/22/2018 01:37 PM ET)
Previous Close$106.45
Today's Range$106.31 - $107.24
52-Week Range$64.80 - $125.86
Volume270,348 shs
Average Volume7.18 million shs
Market Capitalization$168.18 billion
P/E Ratio19.10
Dividend Yield3.62%
Beta1.59

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a strategic collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; and International Myeloma Foundation. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:ABBV
CUSIP00287Y10
Phone847-932-7900

Debt

Debt-to-Equity Ratio8.70
Current Ratio1.20
Quick Ratio1.10

Price-To-Earnings

Trailing P/E Ratio19.10
Forward P/E Ratio13.71
P/E Growth1

Sales & Book Value

Annual Sales$28.22 billion
Price / Sales6.01
Cash Flow$6.6445 per share
Price / Cash16.09
Book Value$3.19 per share
Price / Book33.51

Profitability

EPS (Most Recent Fiscal Year)$5.60
Net Income$5.31 billion
Net Margins21.55%
Return on Equity186.47%
Return on Assets14.42%

Miscellaneous

Employees29,000
Outstanding Shares1,586,880,000

AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, February 15th. Investors of record on Friday, April 13th will be paid a dividend of $0.96 per share on Tuesday, May 15th. This represents a $3.84 dividend on an annualized basis and a dividend yield of 3.59%. The ex-dividend date is Thursday, April 12th. This is a positive change from AbbVie's previous quarterly dividend of $0.71. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its Board of Directors has authorized a stock repurchase program on Friday, February 16th 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's management believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings results on Thursday, April, 26th. The company reported $1.87 earnings per share for the quarter, topping analysts' consensus estimates of $1.79 by $0.08. The business had revenue of $7.93 billion for the quarter, compared to analysts' expectations of $7.60 billion. AbbVie had a net margin of 21.55% and a return on equity of 186.47%. The company's revenue was up 21.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.28 EPS. View AbbVie's Earnings History.

When is AbbVie's next earnings date?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $7.66-7.76 for the period, compared to the Thomson Reuters consensus estimate of $7.53.

What price target have analysts set for ABBV?

16 brokers have issued 12 month price objectives for AbbVie's shares. Their predictions range from $81.00 to $157.00. On average, they anticipate AbbVie's share price to reach $115.6667 in the next twelve months. View Analyst Ratings for AbbVie.

What are Wall Street analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:
  • 1. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well based on strong demand trends, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares have outperformed the industry in the past year supported by a series of positive news including promising data from several pivotal studies, regulatory approvals, including its competitive HCV medicine Mavyret and two approvals for Imbruvica and settlement of its Humira patent disputes with Amgen. In fact. Mavyret has become a major growth driver for AbbVie in a short time on the market. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, Viekira’s sales continue to be hurt by intensifying competition." (3/20/2018)
  • 2. BMO Capital Markets analysts commented, "On its fiscal 3Q18 earnings call, MDT said it does not expect the first-in- human use of its surgical robot in the next couple of months as the company had intended. Recall, MDT had previously said that it expected to be in clinical use by end of its fiscal 2018." (2/15/2018)

Are investors shorting AbbVie?

AbbVie saw a increase in short interest in April. As of April 30th, there was short interest totalling 18,765,949 shares, an increase of 19.8% from the April 13th total of 15,660,655 shares. Based on an average daily trading volume, of 6,014,407 shares, the days-to-cover ratio is presently 3.1 days. Currently, 1.2% of the company's stock are sold short.

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 64)
  • Mr. William J. Chase, Exec. VP & CFO (Age 50)
  • Mr. Michael E. Severino, Exec. VP of R&D and Chief Scientific Officer (Age 52)
  • Ms. Laura J. Schumacher, Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. (Age 55)
  • Mr. Carlos Alban, Exec. VP of Commercial Operations (Age 55)

Has AbbVie been receiving favorable news coverage?

Headlines about ABBV stock have trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AbbVie earned a news sentiment score of 0.15 on Accern's scale. They also assigned news articles about the company an impact score of 47.36 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.30%), Northern Trust Corp (1.36%), Wells Fargo & Company MN (0.80%), Legal & General Group Plc (0.48%), LSV Asset Management (0.39%) and Schwab Charles Investment Management Inc. (0.38%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Epoch Investment Partners Inc., Federated Investors Inc. PA, BlackRock Inc., Wells Fargo & Company MN, Prudential Financial Inc., Swiss National Bank, Legal & General Group Plc and Northern Trust Corp. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Which institutional investors are buying AbbVie stock?

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Mackay Shields LLC, Rock Springs Capital Management LP, SG Americas Securities LLC, Dimensional Fund Advisors LP, Caisse DE Depot ET Placement DU Quebec, Franklin Resources Inc. and ING Groep NV. View Insider Buying and Selling for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $106.96.

How big of a company is AbbVie?

AbbVie has a market capitalization of $168.18 billion and generates $28.22 billion in revenue each year. The company earns $5.31 billion in net income (profit) each year or $5.60 on an earnings per share basis. AbbVie employs 29,000 workers across the globe.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (ABBV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  700 (Vote Outperform)
Underperform Votes:  420 (Vote Underperform)
Total Votes:  1,120
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AbbVie (NYSE:ABBV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
16 Wall Street analysts have issued ratings and price targets for AbbVie in the last 12 months. Their average twelve-month price target is $115.6667, suggesting that the stock has a possible upside of 8.19%. The high price target for ABBV is $157.00 and the low price target for ABBV is $81.00. There are currently 1 sell rating, 8 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.382.382.402.59
Ratings Breakdown: 1 Sell Rating(s)
8 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $115.6667$117.3333$119.0714$95.3750
Price Target Upside: 8.19% upside26.71% upside0.99% upside0.87% upside

AbbVie (NYSE:ABBV) Consensus Price Target History

Price Target History for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2018BMO Capital MarketsReiterated RatingSell$81.00LowView Rating Details
4/30/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$131.00 ➝ $110.00HighView Rating Details
4/27/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$109.00 ➝ $104.00MediumView Rating Details
4/13/2018Jefferies GroupSet Price TargetBuy$122.00LowView Rating Details
4/5/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$120.00 ➝ $102.00LowView Rating Details
3/26/2018Bank of AmericaSet Price TargetHold$120.00HighView Rating Details
2/15/2018Piper Jaffray CompaniesBoost Price TargetOverweight$130.00 ➝ $138.00HighView Rating Details
2/2/2018ArgusBoost Price TargetBuy$120.00 ➝ $145.00LowView Rating Details
1/29/2018Evercore ISIReiterated RatingBuy$144.00LowView Rating Details
1/29/2018SunTrust BanksBoost Price TargetBuy ➝ Average$157.00LowView Rating Details
1/29/2018Leerink SwannDowngradeOutperform ➝ Market Perform$127.00MediumView Rating Details
11/21/2017Societe GeneraleBoost Price TargetN/AView Rating Details
10/13/2017UBSReiterated RatingNeutralN/AView Rating Details
10/11/2017CowenUpgradeMarket Perform ➝ Outperform$91.17 ➝ $105.00N/AView Rating Details
9/28/2017Deutsche BankBoost Price TargetHold$88.00LowView Rating Details
9/8/2017Goldman SachsReiterated RatingBuy$85.00 ➝ $100.00LowView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016CitigroupDowngradeBuy ➝ Neutral$60.00N/AView Rating Details
9/8/2016JPMorgan ChaseDowngradeOverweight ➝ Neutral$75.00 ➝ $73.00N/AView Rating Details
9/1/2016Raymond JamesInitiated CoverageOutperform$82.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

AbbVie (NYSE:ABBV) Earnings History and Estimates Chart

Earnings by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Earnings Estimates

2018 EPS Consensus Estimate: $7.82
2019 EPS Consensus Estimate: $8.59
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$1.79$1.85$1.82
Q2 20184$1.91$2.03$1.97
Q3 20184$1.93$2.15$2.01
Q4 20184$1.88$2.19$2.03
Q1 20192$2.04$2.06$2.05
Q2 20192$2.04$2.20$2.12
Q3 20192$2.07$2.26$2.17
Q4 20192$2.20$2.31$2.26

AbbVie (NYSE ABBV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2018$1.96N/AView Earnings Details
4/26/2018Q1 2018$1.79$1.87$7.6004 billion$7.9340 billionViewN/AView Earnings Details
1/26/2018Q4 2017$1.44$1.48$7.5339 billion$7.7390 billionViewListenView Earnings Details
10/27/2017Q3 2017$1.39$1.41$7.0010 billion$6.9950 billionViewN/AView Earnings Details
7/28/2017Q2 2017$1.40$1.42$6.9301 billion$6.9440 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.2620$1.28$6.4871 billion$6.5380 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AbbVie (NYSE:ABBV) Dividend Information

AbbVie pays an annual dividend of $3.84 per share, with a dividend yield of 3.59%. ABBV's most recent quarterly dividend payment was Tuesday, May 15. The company has grown its dividend for the last 45 consecutive years and is increasing its dividend by an average of 15.50% each year. AbbVie pays out 68.57% of its earnings out as a dividend.
Most Recent Dividend:5/15/2018
Annual Dividend:$3.84
Dividend Yield:3.59%
Dividend Growth:15.50% (3 Year Average)
Payout Ratio(s):68.57% (Trailing 12 Months of Earnings)
49.23% (Based on This Year's Estimates)
43.59% (Based on Next Year's Estimates)
57.79% (Based on Cash Flow)
Track Record:45 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2018quarterly$0.963.36252189141856%4/12/20184/13/20185/15/2018
10/27/2017Quarterly$0.713.12%1/11/20181/12/20182/15/2018
9/8/2017Quarterly$0.642.94%10/12/201710/13/201711/15/2017
6/23/2017quarterly$0.643.52%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.644.14%4/11/20174/13/20175/15/2017
10/28/2016quarterly$0.644.44%1/11/20171/13/20172/15/2017
9/12/2016quarterly$0.573.56%10/12/201610/14/201611/15/2016
6/17/2016quarterly$0.573.8%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.574.2%4/13/20164/15/20165/16/2016
11/2/2015quarterly$0.573.6%1/13/20161/15/20162/16/2016
9/14/2015quarterly$0.513.46%10/13/201510/15/201511/14/2015
6/19/2015quarterly$0.512.94%7/13/20157/15/20158/14/2015
2/20/2015quarterly$0.513.33%4/13/20154/15/20155/15/2015
10/20/2014quarterly$0.493.48%1/13/20151/15/20152/13/2015
9/19/2014quarterly$0.422.86%10/10/201410/15/201411/17/2014
6/19/2014quarterly$0.423.15%7/11/20147/15/20148/15/2014
2/20/2014quarterly$0.423.29%4/11/20144/15/20145/15/2014
12/12/2013quarterly$0.403.06%1/13/20141/15/20142/14/2014
9/19/2013quarterly$0.403.34%10/10/201310/15/201311/15/2013
6/20/2013quarterly$0.403.75%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.404.19%4/11/20134/15/20135/15/2013
1/7/2013special$0.401/11/20131/15/20132/15/2013
1/4/2013quarterly$0.401/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

AbbVie (NYSE ABBV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.07%
Institutional Ownership Percentage: 69.48%
Insider Trading History for AbbVie (NYSE:ABBV)
Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE ABBV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2018Carlos AlbanEVPSell83,574$114.49$9,568,387.26133,026View SEC Filing  
3/1/2018Laura J SchumacherInsiderSell25,000$117.85$2,946,250.00123,317View SEC Filing  
3/1/2018William J ChaseCFOSell70,928$117.18$8,311,343.04203,391View SEC Filing  
2/28/2018Richard A GonzalezChairmanSell8,280$117.88$976,046.40321,292View SEC Filing  
2/28/2018Robert A MichaelVPSell4,294$119.43$512,832.4211,170View SEC Filing  
2/28/2018Timothy J RichmondSVPSell18,129$118.67$2,151,368.4335,717View SEC Filing  
2/20/2018Robert A MichaelVPSell992$120.31$119,347.52View SEC Filing  
12/18/2017Timothy J RichmondSVPSell87,040$98.45$8,569,088.00113,118View SEC Filing  
12/15/2017Laura J SchumacherInsiderSell145,510$96.71$14,072,272.10View SEC Filing  
11/21/2017Richard A GonzalezChairmanSell218,193$94.01$20,512,323.93492,030View SEC Filing  
11/10/2017Michael SeverinoEVPSell25,633$94.69$2,427,188.77114,922View SEC Filing  
10/30/2017Henry O GosebruchInsiderSell18,300$90.55$1,657,065.0081,287View SEC Filing  
9/28/2017Robert A MichaelVPSell6,699$88.00$589,512.0010,007View SEC Filing  
9/11/2017Azita Saleki-GerhardtSVPSell8,300$85.02$705,666.0093,099View SEC Filing  
8/7/2017Richard A GonzalezChairmanSell193,131$71.00$13,712,301.00469,623View SEC Filing  
8/4/2017Richard A GonzalezChairmanSell87,899$71.02$6,242,586.98342,353View SEC Filing  
8/3/2017Richard A GonzalezCEOSell65,861$71.00$4,676,131.00342,353View SEC Filing  
7/31/2017Edward J RappDirectorBuy4,000$70.45$281,800.0015,498View SEC Filing  
7/31/2017Henry O GosebruchInsiderSell18,000$70.09$1,261,620.0096,074View SEC Filing  
6/14/2017Carlos AlbanEVPSell45,800$70.00$3,206,000.00160,545View SEC Filing  
6/14/2017Laura J SchumacherInsiderSell79,800$70.00$5,586,000.00187,625View SEC Filing  
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15349,462View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00209,043View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00114,745View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00147,415View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.2816,706View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.7926,078View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00369,113View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00178,970View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00144,138View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18260,438View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46624,374View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00338,421View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76149,444View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.0068,204View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.1644,615View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00199,238View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.3079,064View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80395,403View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.7585,828View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38205,138View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56180,068View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.3266,703View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.7064,279View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.4164,237View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AbbVie (NYSE ABBV) News Headlines

Source:
DateHeadline
Top Analyst Reports for Procter & Gamble, AbbVie, McDonalds & PepsiCoTop Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo
www.zacks.com - May 21 at 3:11 PM
Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCoTop Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo
finance.yahoo.com - May 21 at 3:11 PM
Roche (RHHBY) Announces Positive Data on Hemophilia DrugRoche (RHHBY) Announces Positive Data on Hemophilia Drug
finance.yahoo.com - May 21 at 3:11 PM
BRIEF-AbbVie Inc Says On May 17, Entered Loan Credit Agreement To Borrow Up To $3 BlnBRIEF-AbbVie Inc Says On May 17, Entered Loan Credit Agreement To Borrow Up To $3 Bln
www.reuters.com - May 19 at 5:13 AM
Investors bullish on biotechs after Trump drug pricing speechInvestors bullish on biotechs after Trump drug pricing speech
seekingalpha.com - May 18 at 3:07 PM
5 Things AbbVie Investors Need to Know5 Things AbbVie Investors Need to Know
finance.yahoo.com - May 18 at 3:07 PM
AbbVie (ABBV) option implied volatility, to present investigational oncology portfolio at ASCOAbbVie (ABBV) option implied volatility, to present investigational oncology portfolio at ASCO
www.streetinsider.com - May 18 at 5:04 AM
AbbVie Inc. (ABBV) Receives Average Rating of "Buy" from BrokeragesAbbVie Inc. (ABBV) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 17 at 3:31 PM
AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual ...AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual ...
www.prnewswire.com - May 17 at 5:40 AM
Trump’s Attempt to Shame Drugmakers Shows Medicare Costs SoaringTrump’s Attempt to Shame Drugmakers Shows Medicare Costs Soaring
finance.yahoo.com - May 16 at 5:01 AM
AstraZeneca’s 1Q18 Estimates: Segment-by-Segment RevenuesAstraZeneca’s 1Q18 Estimates: Segment-by-Segment Revenues
finance.yahoo.com - May 15 at 3:01 PM
AbbVie Inc. (ABBV) Short Interest Up 19.8% in AprilAbbVie Inc. (ABBV) Short Interest Up 19.8% in April
www.americanbankingnews.com - May 15 at 2:56 AM
Oryzon Genomics commences mid-stage study of Alzheimers candidateOryzon Genomics commences mid-stage study of Alzheimer's candidate
seekingalpha.com - May 14 at 3:10 PM
The Trump Plan To Reduce Prescription Drug Prices Will Have A Major ImpactThe Trump Plan To Reduce Prescription Drug Prices Will Have A Major Impact
finance.yahoo.com - May 14 at 3:10 PM
$8.24 Billion in Sales Expected for AbbVie Inc. (ABBV) This Quarter$8.24 Billion in Sales Expected for AbbVie Inc. (ABBV) This Quarter
www.americanbankingnews.com - May 13 at 2:52 AM
Zacks: Brokerages Expect AbbVie Inc. (ABBV) Will Announce Earnings of $1.97 Per ShareZacks: Brokerages Expect AbbVie Inc. (ABBV) Will Announce Earnings of $1.97 Per Share
www.americanbankingnews.com - May 11 at 5:37 PM
Trump plan on drug prices to be announced this afternoonTrump plan on drug prices to be announced this afternoon
seekingalpha.com - May 11 at 3:20 PM
Global $113 Bn Immunology Drugs Market, 2023: Key Players are AbbVie, Johnson & Johnson, Novartis, Pfizer, Roche ...Global $113 Bn Immunology Drugs Market, 2023: Key Players are AbbVie, Johnson & Johnson, Novartis, Pfizer, Roche ...
www.prnewswire.com - May 11 at 5:19 AM
How Much Upside Do Analysts Expect from AbbVie?How Much Upside Do Analysts Expect from AbbVie?
finance.yahoo.com - May 10 at 3:10 PM
Analyzing AbbVie’s Humira, Imbruvica, and HCV ProductsAnalyzing AbbVie’s Humira, Imbruvica, and HCV Products
finance.yahoo.com - May 10 at 3:10 PM
Analyzing AbbVie’s Product PerformanceAnalyzing AbbVie’s Product Performance
finance.yahoo.com - May 10 at 3:10 PM
Analyzing AbbVie’s Financial PerformanceAnalyzing AbbVie’s Financial Performance
finance.yahoo.com - May 10 at 3:10 PM
Exploring AbbVie’s Research Programs in Oncology and NeurologyExploring AbbVie’s Research Programs in Oncology and Neurology
finance.yahoo.com - May 10 at 3:10 PM
Exploring the Key Aspects of AbbVie’s Research PipelineExploring the Key Aspects of AbbVie’s Research Pipeline
finance.yahoo.com - May 10 at 3:10 PM
What’s AbbVie’s Business Strategy for 2018?What’s AbbVie’s Business Strategy for 2018?
finance.yahoo.com - May 10 at 3:10 PM
Exploring AbbVie’s Cash FlowsExploring AbbVie’s Cash Flows
finance.yahoo.com - May 10 at 3:10 PM
Why Did Biogen and AbbVie Recall Zinbryta?Why Did Biogen and AbbVie Recall Zinbryta?
finance.yahoo.com - May 8 at 3:02 PM
AbbVie to Present at the UBS Global Healthcare ConferenceAbbVie to Present at the UBS Global Healthcare Conference
finance.yahoo.com - May 8 at 3:02 PM
Celgene’s Otezla Witnessed Solid Growth in 1Q18Celgene’s Otezla Witnessed Solid Growth in 1Q18
finance.yahoo.com - May 8 at 3:02 PM
Biogen’s Key Partnerships: Eisai, Pfizer, AbbVie, and IonisBiogen’s Key Partnerships: Eisai, Pfizer, AbbVie, and Ionis
finance.yahoo.com - May 8 at 3:02 PM
Keytruda: Merck’s Immuno-Oncology Blockbuster Drug in 1Q18Keytruda: Merck’s Immuno-Oncology Blockbuster Drug in 1Q18
finance.yahoo.com - May 8 at 3:02 PM
Form 3 AbbVie Inc. For: May 04 Filed by: Roberts Rebecca BForm 3 AbbVie Inc. For: May 04 Filed by: Roberts Rebecca B
www.streetinsider.com - May 8 at 5:15 AM
How Amgen’s Enbrel and Neulasta Performed in 1Q18How Amgen’s Enbrel and Neulasta Performed in 1Q18
finance.yahoo.com - May 7 at 3:14 PM
Allergan’s US General Medicines Segment in 1Q18Allergan’s US General Medicines Segment in 1Q18
finance.yahoo.com - May 7 at 8:01 AM
AbbVie, Snap, Spotify, Xerox: Fast Money Picks For May 3AbbVie, Snap, Spotify, Xerox: 'Fast Money' Picks For May 3
www.benzinga.com - May 3 at 3:11 PM
Form SC TO-I/A AbbVie Inc. Filed by: AbbVie Inc.Form SC TO-I/A AbbVie Inc. Filed by: AbbVie Inc.
www.streetinsider.com - May 3 at 3:11 PM
AbbVie Inc. (ABBV) Expected to Earn FY2019 Earnings of $9.04 Per ShareAbbVie Inc. (ABBV) Expected to Earn FY2019 Earnings of $9.04 Per Share
www.americanbankingnews.com - May 3 at 10:08 AM
"Fast Money" final trades: SNAP, SPOT and more"Fast Money" final trades: SNAP, SPOT and more
finance.yahoo.com - May 3 at 5:12 AM
AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care ConferenceAbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference
www.prnewswire.com - May 2 at 3:10 PM
9 Winning Stocks as the Bull Loses Steam9 Winning Stocks as the Bull Loses Steam
finance.yahoo.com - May 2 at 3:10 PM
Q2 2018 EPS Estimates for AbbVie Inc. (ABBV) Raised by AnalystQ2 2018 EPS Estimates for AbbVie Inc. (ABBV) Raised by Analyst
www.americanbankingnews.com - May 2 at 9:10 AM
BRIEF-Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For ...BRIEF-Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For ...
www.reuters.com - May 1 at 3:02 PM
AbbVie (ABBV) Submits MAA to EMA for Investigational Treatment Risankizumab for Moderate to Severe Plaque ...AbbVie (ABBV) Submits MAA to EMA for Investigational Treatment Risankizumab for Moderate to Severe Plaque ...
www.streetinsider.com - May 1 at 3:02 PM
AbbVie (ABBV) Commences Self-Tender Offer for Up to $7.5 Billion of its Common StockAbbVie (ABBV) Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock
www.streetinsider.com - May 1 at 3:02 PM
AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment ...AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment ...
www.prnewswire.com - May 1 at 3:02 PM
Drugmakers eye a new threat to sales but say it hasn’t affected them — yetDrugmakers eye a new threat to sales but say it hasn’t affected them — yet
finance.yahoo.com - May 1 at 3:02 PM
How AbbVie Fared in 1Q18How AbbVie Fared in 1Q18
finance.yahoo.com - May 1 at 3:02 PM
AbbVie’s Humira and Imbruvica: 1Q18 PerformanceAbbVie’s Humira and Imbruvica: 1Q18 Performance
finance.yahoo.com - May 1 at 3:02 PM
AbbVie’s Hepatitis C Franchise, Kaletra, and Synagis in 1Q18AbbVie’s Hepatitis C Franchise, Kaletra, and Synagis in 1Q18
finance.yahoo.com - May 1 at 3:02 PM
AbbVie (ABBV) Rating Reiterated by BMO Capital MarketsAbbVie (ABBV) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - May 1 at 1:28 PM

SEC Filings

AbbVie (NYSE:ABBV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AbbVie (NYSE:ABBV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AbbVie (NYSE ABBV) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.